#Israel #Compugen #Holon #Unigen #COM701

Compugen's Virtual KOL Event on Ovarian Cancer Insights

On October 5, 2026, Compugen Ltd. will host a significant virtual event focused on its innovative antibody, COM701, primarily aimed at treating ovarian cancer. This event, set to commence at 8:00 AM ET, will feature renowned oncologist Dr. Oladapo Yeku from Harvard Medical School, who will discuss the evolving therapeutic landscape for ovarian cancer patients.

Event Highlights

During this online gathering, attendees will have the unique opportunity to hear from Dr. Yeku, who serves as a key opinion leader in gynecologic oncology. A focal point of the discussion will be the MAIA-ovarian adaptive platform trial that investigates the efficacy and safety of COM701, a first-in-class anti-PVRIG antibody. This novel therapeutic approach is designed for maintenance treatment in patients experiencing relapsed platinum-sensitive ovarian cancer (PSOC).

Dr. Yeku is expected to shed light on the trial's design and objectives, including the anticipated median progression-free survival data projected for Q1 2027. This interim analysis will provide crucial insights into the antibody's potential as a game-changer in ovarian cancer treatment protocols.

Compugen’s internal research and discovery team will also share exciting advancements regarding the Unigen™ platform, an AI/ML-driven tool that enhances target discovery and development for cancer immunotherapeutics. The team's updates will showcase how Unigen™ fuels the progress of cutting-edge immuno-oncology innovations.

About COM701 and the Future of Ovarian Cancer Treatments

COM701 is currently undergoing clinical trials, having shown promising results in initial phases as both a standalone treatment and in combination therapies. Its primary goal is to improve outcomes for patients with relapsed PSOC by demonstrating robust anti-tumor activity while maintaining a favorable safety profile. Attendees of the event will learn not just about COM701 but also the broader implications such therapies hold for future cancer treatment.

Who is Dr. Oladapo Yeku?

Dr. Yeku is an esteemed Associate Professor of Medicine at Harvard Medical School and is pivotal in the Gynecologic Oncology Program at Massachusetts General Hospital. His expertise lies in immunotherapy for gynecologic cancers, and he spearheads numerous trials aimed at eliminating the challenges faced by ovarian cancer patients.

Throughout the event, there will also be a live Q&A session, allowing participants to dive deeper into the discussion and engage with the experts directly.

Registration Details

To participate in this pivotal discussion, interested parties can register online. This event promises to provide valuable insights into the future trajectory of ovarian cancer treatment and highlights Compugen's commitment to advancing cancer immunotherapies.

As the landscape shifts towards personalized and precise cancer treatments, events like these serve to educate healthcare providers and the public alike, potentially changing the future of how these diseases are tackled. Compugen continues to lead the charge with innovative solutions backed by cutting-edge research and development methodologies.

Mark your calendars for October 5, 2026, and be part of the conversation!

For further details on the registration process, visit Compugen’s official website or their Investor Relations page.